Phase 3 Multicenter, Double-Blind, randomized, placebo-controlled trail of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302)
- Satkunasivam, Raj (PI)
- Singh, Monisha (Key Personnel)
- Zhang, Jun (Key Personnel)
Project: Clinical Trial